In early research, tazemetostat has demonstrated anticancer efficacy in a variety of cancers with functional deletion mutations of the SWI/SNF complex or abnormal activation of EZH2 resulting in histone hypermethylation, such as sarcoma, non-Hodgkin's lymphoma, medulloblastoma, and many solid tumors [32]. This evidence concerns the gene EZH2 and cancer.